SNTI - Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

• Chardan Capital Markets has initiated Senti Biosciences ( NASDAQ: SNTI ) with a buy highlighting the potential of the company's gene circuit synthetic biology platform and engineered cell therapy pipeline.
• The firm says the platform and pipeline can "address several limitations of current cell and gene therapy modalities."
• Chardan has a price target of $12 (757% upside based on Thursday's close).
• "Senti ( SNT ) has developed a suite of technologies including logicgates, calibrated-release cytokines, small-molecule regulated promoters....[that] can be used independently or in concert to achieve an optimized therapeutic profile across multiple modalities including various engineered cell therapy types as well as viral vectors," Chardan analyst wrote.
• Senti has two candidates based on donor-derived CAR-NK cells: SENTI-202 for acute myeloid leukemia, and SENTI-301 for hepatocellular carcinoma. Both are expected to enter the clinic next year.

For further details see: